article = {COR-2020-7-111}
title = {Real World Patterns of PSA Response and Survival with Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer (mCRPC)}
journal = {Clinical Oncology and Research}
year = {2020}
issn = {2613-4942}
doi = {http://dx.doi.org/10.31487/j.COR.2020.07.11}
url = {https://www.sciencerepository.org/real-world-patterns-of-psa-response-and-survival-with-abiraterone_COR-2020-7-111 
author = {Michael Rowe,Stuart  Walter,Ayesha  Hidayat,Hannah  Donkers,Andrew  Browne,Timothy  Norris,Adam  Pollard,Deborah  Victor,John McGrane,}
keywords = {Metastatic prostate cancer, enzalutamide, abiraterone, androgen receptor targeted agents, treatment sequence}
abstract ={Background: We investigated our institution’s mCRPC enzalutamide or abiraterone patients examining
PSA responses and impact of sequencing of these drugs.
Methods: All enzalutamide / abiraterone mCRPC patients (2011-2018) were included. Rates of PSA >50%
response (PSA50) were compared. Time to treatment failure (TTF) and overall survival (OS) was analysed
as per lines of previous therapy and timing of chemotherapy.
Results: 363 patients included (Enza n=236, Abi n=127), with 15.6 months median follow-up. PSA50 was
greater in enzalutamide group (58% vs 31% p<0.0005) but TTF was similar for both groups (median Abi
4.2m vs Enza 6m, p=0.965). There was no significant median OS difference between the groups (Enza
13.8m vs Abi 12.5m p=0.065). Number of lines of prior therapy (p=0.735) or timing of chemotherapy before
or after Abi/Enza (p=0.21) had no significant OS impact.
Conclusion: Enzalutamide showed higher PSA50 response than abiraterone. Previous lines of therapy or
sequencing of chemotherapy with abiraterone / enzalutamide showed no significant survival differences
indicating no detriment in either treatment sequence.}